279 related articles for article (PubMed ID: 29152762)
1. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
Yurdaydin C; Keskin O; Yurdcu E; Çalişkan A; Önem S; Karakaya F; Kalkan Ç; Karatayli E; Karatayli S; Choong I; Apelian D; Koh C; Heller T; Idilman R; Bozdayi AM; Glenn JS
Hepatology; 2022 Jun; 75(6):1551-1565. PubMed ID: 34860418
[TBL] [Abstract][Full Text] [Related]
3. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Koh C; Canini L; Dahari H; Zhao X; Uprichard SL; Haynes-Williams V; Winters MA; Subramanya G; Cooper SL; Pinto P; Wolff EF; Bishop R; Ai Thanda Han M; Cotler SJ; Kleiner DE; Keskin O; Idilman R; Yurdaydin C; Glenn JS; Heller T
Lancet Infect Dis; 2015 Oct; 15(10):1167-1174. PubMed ID: 26189433
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
6. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
[TBL] [Abstract][Full Text] [Related]
8. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
9. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial.
Gheorghe L; Iacob S; Simionov I; Vadan R; Constantinescu I; Caruntu F; Sporea I; Grigorescu M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):377-82. PubMed ID: 22187703
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
12. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.
Lamers MH; Kirgiz ÖÖ; Heidrich B; Wedemeyer H; Drenth JP
Antivir Ther; 2012; 17(6):1029-37. PubMed ID: 22892440
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis D: an unmet medical need.
Caviglia GP; Rizzetto M
Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
[TBL] [Abstract][Full Text] [Related]
16. Antiviral treatment and liver-related complications in hepatitis delta.
Wranke A; Serrano BC; Heidrich B; Kirschner J; Bremer B; Lehmann P; Hardtke S; Deterding K; Port K; Westphal M; Manns MP; Cornberg M; Wedemeyer H
Hepatology; 2017 Feb; 65(2):414-425. PubMed ID: 27770553
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
Samiullah S; Bikharam D; Nasreen
World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.
Canini L; Koh C; Cotler SJ; Uprichard SL; Winters MA; Han MAT; Kleiner DE; Idilman R; Yurdaydin C; Glenn JS; Heller T; Dahari H
Hepatol Commun; 2017 Jun; 1(4):288-292. PubMed ID: 29404459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
